Introduction
Peritonitis due to Candida has recently been reviewed by Bayer et al. (1976) . Their report and that by Bortolussi et al. (1975) suggested that short-term therapy with amphotericin B administered intravenously, intraperitoneally, or by a combination of these routes was effective in the treatment of Candida peritonitis.
A patient with peritonitis due to C. albicans is now described who received only intravenous amphotericin B. Simultaneous serum and peritoneal fluid levels of this antifungal agent were determined, and in spite of adequate peritoneal fluid concentrations of amphotericin B, Candida organisms were demonstrated microscopically in the gall-bladder at post-mortem.
Case report
A 48-year-old barman was transferred to the Minneapolis Veterans Administration Hospital for evaluation of abdominal pain and haematemesis. During the three weeks before transfer he had been (Fig. 1) .
Discussion
Clinically significant peritoneal infection with Candida has been described, manifest by fever, signs of peritoneal inflammation, positive peritoneal cultures, and purulent ascitic fluid (Bayer et al., 1976) . The patient fulfilled all these criteria although fever greater than 38°C was present only on the day of the second laparotomy. There was no evidence of disseminated candidiasis in that all intraperitoneal vessels were patent and no yeast was ever found outside the abdominal cavity.
Intraperitoneal administration of amphotericin B for the treatment of Candida peritonitis has been proposed in order to decrease the systemic reactions frequently encountered with the intravenous injection of this agent (Bayer et al., 1976) . This method of therapy has been thought to be effective because Candida organisms usually remain localized to the abdominal cavity. The dosages recommended have varied widely. Bortolussi et al. (1975) (Bennett, 1974; Feldman, Hamilton and Gutman, 1973) . The present authors show for the first time that intravenously administered amphotericin B penetrates well into inflamed peritoneal fluid, with a peak-fluid:
peak-serum penetration ratio of 52%. Increased penetration into aqueous humour has been reported with ocular inflammation in experimental animals (Green, Bennett and Goos, 1965 Barnes et al. (1975) and in earlier reports (Montemartini, Specchia and Dander, 1970; Reeves et al., 1972) . Oral administration of amphotericin B has been used (Hurwich, 1966) and may be effective in the gut lumen, but the poor absorption of swallowed amphotericin B would make this an unreliable approach for the treatment of Candida peritonitis.
Finally, it is noteworthy that the patient here reported received antibiotics for 3 weeks before the onset of Candida peritonitis, and that C. albicans was recovered from his sputum 4 days before the development of peritoneal signs. The role of antecedent systemic antibacterial therapy and intraperitoneal administration of antimicrobials as predisposing factors in the development of peritoneal candidiasis was cited by Bayer et al. (1976) . It is likely that the colonization of the present patient's upper respiratory tract with C. albicans led to the eventual development of Candida peritonitis following gastric ulcer perforation.
In summary, the authors have shown that amphotericin B penetrates well into the inflamed peritoneal cavity, and that in the presence of peritonitis Candida organisms may infect intra-abdominal organs without specific localizing signs. Therefore, to ensure adequate drug penetration into all infected sites, the authors recommend either high dose intravenous, high dose intraperitoneal or a combination of these two methods of therapy for patients treated with amphotericin B, and continuation of therapy for at least as long as signs of peritoneal infection persist.
